| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 144.2 KB | Adobe PDF |
Advisor(s)
Abstract(s)
According to the International Diabetes Federation, Diabetes mellitus type 2 (DM2) has affected more than 425 million people in 2017 worldwide]. Not only is it a disease responsible for more than 4 million deaths, but also a trigger for other non communicable diseases and a huge burden on national health systems. The most important clinical manifestation of T2DM is hyperglycemia and monitoring of blood glucose levels remains the only method of screening. However, when glucose levels are high, the disease is already in place. The large investment in DM2 research allowed the identification of biomarkers that could be used to describe the progression of diabetes and some were described as having a predictive potential value to differentiate between progressors / non-progressors. One of the biomarkers described is Galectin-3 (Gal3). Previous studies of our group have already demonstrated a correlation of Gal3 between diabetic and non-diabetic animals.
Description
Keywords
Type 2 diabetes Early diagnosis Galectin-3
Citation
Luis, C., Soares, R., Baylina, P., & Fernandes, R. (2019). Galectin-3: A biomarker of metabolic progression of type 2 diabetes? Workshop on R&D Projects: Proceedings, 22–23.